Summary: Centessa Pharmaceuticals has made progress in its orexin receptor 2 agonist program, focusing on the development of treatments for sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. The company has initiated a phase 1 clinical trial for ORX750, with … [Read more...]
Centessa on Track to Unveil ORX750 Data for Sleep Disorders
Essential Takeaways: Centessa Prescribed drugs claimed development in its orexin agonist software, spotlighting the possible of ORX750 to treat narcolepsy and other rest-wake diseases centered on promising preclinical details. ORX750 demonstrated usefulness in cutting down … [Read more...]